Inhibikase swaps 18,030,000 shares for RA Capital pre-funded warrant in unregistered offering

• Inhibikase Therapeutics entered an exchange agreement on July 29, 2026 with RA Capital Healthcare Fund.
• RA Capital exchanged 18,030,000 common shares for a pre-funded warrant to buy 18,030,000 common shares.
• The pre-funded warrant is immediately exercisable at $0.001 per share with no expiration date.
• Exercise is capped by a 9.99% beneficial ownership blocker, adjustable on 61 days’ notice up to 19.99%.
• The unregistered issuance relied on the Securities Act Section 3(a)(9) exemption.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibikase Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-323651), on July 29, 2026, and is solely responsible for the information contained therein.